Rosen, the lead law firm at BioEdge Labs, encourages investors to wait for advice before the necessary time frame in a securities class action.

Spread the love

NEW YORK, NY–(The News File Corporation – January 18, 2025) – why: Rosen Law Firm, a global investor rights law firm, represented the purchasers of BioAge Labs, Inc. (NASDAQ: BIOA) shares pursuant to BioEdge’s registration statement and/or for its initial public offering (“IPO”) on September 26, 2024. “), the relevant March 10, 2025 Lead Plaintiff Deadline.

So what? If you buy BioAge stock, you may receive compensation through a contingent payment arrangement without paying any out-of-pocket fees or expenses.

What to do next: To join a BioAge class action, go to or call Philip Kim, Esq. Toll free at 866-767-3653 or email case@rosenlegal.com for class action information. A class action lawsuit has already been filed. If you want to serve as lead plaintiff, you must move the court After 10 March 2025. A lead plaintiff is a representative party who conducts litigation on behalf of other class members.

Why the Rose Rule? We encourage investors to select a qualified advisor with a track record of success in a leadership role. Oftentimes, the organizations that issue the ads don’t have comparable experience, resources, or any meaningful peer recognition. Most of these firms do not litigate securities class actions but are intermediaries who refer clients or litigate cases with law firms. Be wise when choosing advice. The Rosen Law Firm represents investors worldwide, focusing its practice on securities class actions and shareholder derivative litigation. Rosen Law Firm brought the largest securities class action against a Chinese company at the time. Rosen Law Firm is rated Class 1 by ISS Securities. Action (WA:) Services in 2017 for the securities division of the action settlement number. The firm has been ranked in the top 4 every year since 2013 and has returned hundreds of millions of dollars to investors. In the year In 2019 alone, the company raised over $438 million for investors. In the year In 2020, founding partner Lawrence Rosen was named a Titan of the Plaintiffs Bar by Law360. Many of the firm’s lawyers are accredited by Laudragon and Super Lawyers.

Details of the case:- According to the lawsuit, the defendants offered the lead candidate, azelaprag, in connection with BioAge’s ongoing STRIDES clinical trial, which is expected to reach peak results in 2025. A clinical development organization that advises and assists with all aspects of STRIDES trial design and execution. The defendants discussed the potential for a second phase 2 clinical trial of a combination of azelaprag and semaglutide in individuals aged 18 and older. Therefore, the IPO represented to the public that there were no safety concerns and that BioAge expected top-line results and met its primary endpoints related to the STRIDES clinical trial.

Contrary to these representations, BioAge has halted the ongoing STRIDES phase 2 study of its investigational drug candidate azelaprag, warning that it could cause organ damage after several subjects showed elevated levels of liver enzymes. As a result, defendants terminated the clinical trial and halted further enrollment. Given the fact that Defendants failed to disclose the potential for liver transaminases in previous clinical Phase 1 trials and various preclinical toxicity studies, Defendants’ representations in BioAge’s registration statement at the time of IPO were false and/or materially misleading. Investors were harmed, the lawsuit says, when the correct listings entered the market.

To join the BioAge class action, go to or call Philip Kim, Esq. Toll free at 866-767-3653 or email case@rosenlegal.com for class action information.

No class confirmed. Unless a unit is confirmed, you will not be represented by a consultant unless you have booked one. You can choose the advice of your choice. You can also remain a member of a class you are not in and do nothing at this point. An investor’s ability to participate in any future recovery is not dependent on serving as a lead plaintiff.

Notice of attorney. Previous results do not guarantee the same result.

————————————-

To view the source of this press release, please visit https://www.newsfilecorp.com/release/237658.